<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57045">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02363439</url>
  </required_header>
  <id_info>
    <org_study_id>8400-404</org_study_id>
    <nct_id>NCT02363439</nct_id>
  </id_info>
  <brief_title>Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401</brief_title>
  <official_title>An Extension Study to Evaluate the Long-Term Safety, Tolerability, and Clinical Activity of IMO-8400 in Patients With Relapsed or Refractory Waldenström's Macroglobulinemia Who Completed Study 8400-401</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idera Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idera Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An extension study for patients who complete 24 weeks of IMO-8400 on study 8400-401.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who had no evidence of disease progression or toxicity while participating in study
      8400-401 will continue to receive IMO-8400 until disease progression, adverse event or the
      investigator deems the goals of extended treatment with IMO-8400 have been met.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>Treatment until progression, intolerable adverse event or investigator deems goals of treatment met (an expected average of 1 year)</time_frame>
    <description>Long term safety and tolerability of IMO-8400 in patients with Waldenstrom's Macroglobulinemia who have completed 24 weeks of treatment in Protocol 8400-401 without evidence of disease progression or toxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure total and monoclonal IgM levels</measure>
    <time_frame>Treatment until progression, intolerable adverse event or investigator deems goals of treatment met (an expected average of 1 year)</time_frame>
    <description>To assess the long-term treatment effect (clinical activity) of IMO-8400 using disease-specific international guidelines for classifying clinical response (including total and monoclonal IgM and clinical symptoms)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Waldenstrom's Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>IMO-8400 at one of three dose levels</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose levels defined per Protocol 8400-401</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMO-8400</intervention_name>
    <description>IMO-8400 at 0.6, 1.2 or 2.4 mg/kg/wk as defined per Protocol 8400-401</description>
    <arm_group_label>IMO-8400 at one of three dose levels</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completed 24 weeks of treatment in Protocol 8400-401

        Exclusion Criteria:

          -  Grade 3 (or higher) adverse event assessed as treatment-related at any time during
             the course of treatment under Protocol 8400-401.

          -  Has evidence of disease progression under Protocol 8400-401.

          -  Has received other anti-cancer therapies other than IMO-8400 since enrolling in
             Protocol 8400-401.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Cornfeld, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Idera Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 6, 2017</lastchanged_date>
  <firstreceived_date>November 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
